-
Mashup Score: 0
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2HR+ Breast Cancer Treatment Algorithm - 6 day(s) ago
Rohit Gosain MD; Rahul Gosain, MD; and Kevin Kalinsky, MD, discuss an overview of hormone receptor–positive (HR+) breast cancer treatment, treatment of locally advanced diseases, treatment options for metastatic breast cancer, and sequencing treatment for endocrine-resistant disease.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
🚨 Catch up on an all-new Treatment Algorithms with the @OncBrothers and @drsarahsam discussing HER2+ breast cancer. It's an episode not to be missed. #bcsm | @DanaFarber Watch the full episode here 👇 https://t.co/aCl1LEbzsC https://t.co/1rr7CBpw6C
-
-
Mashup Score: 0
Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Lenvatinib/belzutifan had durable antitumor activity in patients with histologically confirmed locally advanced or metastatic ccRCC after progression on or following PD-L1 inhibitor or VEGF-tyrosine kinase inhibitor treatment. #GU25 @katy_beckermann https://t.co/PZOBdqUVXz
-
-
Mashup Score: 0
The TALAPRO-2 trial revealed promising survival data for patients with metastatic CRPC treated with talazoparib and enzalutamide.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A significant overall survival benefit has been observed in patients with metastatic castration-resistant prostate cancer treated with the combination of talazoparib and enzalutamide. #GU25 #pcsm | @neerajaiims @ASCO https://t.co/FwF0UQbvg6
-
-
Mashup Score: 0
Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment. #lymsm | @JuanAlderuccio https://t.co/TfMQN3Q2Bb
-
-
Mashup Score: 0
Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Retreatment with pertuzumab combined with trastuzumab emtansine plus physician’s choice of chemotherapy may improve survival outcomes in patients with HER2–positive locally advanced or metastatic breast cancer. #bcsm https://t.co/smtOWkl7Yg
-
-
Mashup Score: 0
The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases. #bcsm | @DrVKGadi @RutaRaoMD @jane_meisel https://t.co/YQqz24kl8j
-
-
Mashup Score: 0
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills. #oncology https://t.co/YWEtqu2v6k
-
-
Mashup Score: 0
Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range. #bcsm | @dradityabardia https://t.co/4uclw3Yy6i https://t.co/iHIrDZrAFL
-
-
Mashup Score: 4Creating a Collaborative Edge Through the MZL Workshop - 10 day(s) ago
Julie M. Vose, MD, MBA, answered questions about the significance and potential impact of MZL Workshop.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
"Since it is such a rare disease, we do need to work collaboratively and work on clinical trials together with a lot of different centers to try to pool our data," said Julie M. Vose, MD, MBA. #lymsm | @lymphoma @DrJulieVose https://t.co/Xefdfi3UbP
-
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state. #lymsm | @lymphoma @DrJulieVose https://t.co/WMAv4TVgjC https://t.co/Lqys6ZCZrw